Clinical trial · Observational
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Castration Resistant Prostate Cancer (mCRPC) | Castration-Resistant Prostate Carcinoma | CURATED_BROADER | 0.78 |
| Metastatic Castration Sensitive Prostate Cancer (mCSPC) | — | UNRESOLVED | — |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| abiraterone | Drug | Abiraterone | ALIAS |
| apalutamide | Drug | Apalutamide | ALIAS |
| cabazitaxel | Drug | Cabazitaxel | ALIAS |
| degarelix | Drug | Degarelix | ALIAS |
| docetaxel | Drug | Docetaxel | ALIAS |
| enzalutamide | Drug | Enzalutamide | ALIAS |
| goserelin | Drug | Goserelin | ALIAS |
| leuprorelin | Drug | Leuprolide | ALIAS |
| Lutetium-177 |
Design
Arms and outcomes
Arms (2)
- label
- Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)
- interventionNames
- Drug: degarelix
- Drug: goserelin
- Drug: leuprorelin
- Drug: triptorelin
- label
- Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)
- interventionNames
- Drug: abiraterone
- Drug: enzalutamide
- Drug: docetaxel
- Drug: apalutamide
- Drug: cabazitaxel
- Drug: Radium-223
- Drug: Lutetium-177
Primary outcomes (28)
- measure
- Body Mass Index (BMI)
- timeFrame
- 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022 * Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC) * Detection of metastatic prostate cancer Exclusion Criteria: * Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014 * Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
References
Publications (1)
- DERIVEDMoisander M, Holsa O, Teittinen K, Kysenius K, Kosunen M, Lehmus L, Murtola TJ. Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014-2022 in Pirkanmaa, Finland-an observational study. Ther Adv Urol. 2026 May 27;18:17562872261451289. doi: 10.1177/17562872261451289. eCollection 2026 Jan-Dec. PMID 42221687